Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to
be Presented at Upcoming ASH Meeting
QUÉBEC CITY, Nov. 26, 2012 /CNW
Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
today announced that final Phase 2 data for perifosine, its oral
AKT inhibitor, combined with sorafenib in patients with
relapsed/refractory lymphomas, will be presented at the upcoming
American Society of Hematology ("ASH") annual meeting in
Atlanta, Georgia, December 8-11, 2012. Data will be disclosed
during a poster presentation by Anna
Guidetti, MD, of the Fondazione IRCCS Instituto Nazionale
Tumori, Milan, Italy.
Abstract
#3679: |
"Dual Targeted Therapy with the AKT Inhibitor Perifosine and
the Multikinase Inhibitor Sorafenib in Patients with
Relapsed/Refractory Lymphomas: Final Results of a Phase 2
Trial", A Guidetti, S. Viviani, A. Marchiano, A. Dodero, L.
Farina, S.L. Locatelli, D. Russo, P. Bulian, R. Sorasio, M. Di
Nicola, L. Giordano, P. Corradini, A.M. Gianni,
C. Carlo-Stella. |
|
|
Poster Session
#624: |
"Lymphoma-Therapy with Biologic Agents, Excluding
Pre-Clinical Models: Poster III" |
Date &
Time: |
Monday, December 10, 2012, from 6 pm to 8 pm
(Eastern) |
Venue: |
Georgia World Congress Center, Hall B1-B2, Level 1, Building
B |
About Perifosine
Perifosine is a novel, oral anticancer treatment that inhibits
Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. It
has been granted orphan drug and orphan medicinal product
designations for multiple myeloma ("MM") from the FDA and the
European Medicines Agency ("EMA"), respectively. Perifosine
has also received Fast Track designation from the FDA. The
ongoing Phase 3 trial in MM is conducted under a Special Protocol
Assessment from the FDA and a positive Scientific Advice from the
EMA, with positive results from this trial expected to be
sufficient for registration in the US and Europe. Perifosine is also being explored in
combination therapy and in monotherapy in other cancer indications.
Aeterna Zentaris holds worldwide rights to perifosine except for
Japan, Korea and MENA
(Middle East and North Africa) region, where licensing rights
have been granted to Yakult Honsha, Handok and Hikma
Pharmaceuticals respectively.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.